Appointments: EMD Serono, Cellectis, Shire, Bayer, Biogen, Horizon, Alligator, Faron, Ironwood, Vectura
Executive Summary
The latest biopharma industry appointments include R&D leadership appointments at Shire, Bayer, Alligator and Horizon Pharma, new chief medical officers for Shire and Alligator, and a new chief commercial officer for Faron Pharmaceuticals. Meanwhile, Biogen has brought in a new chief information officer.
You may also be interested in...
Shire Tempts Busch From Bayer As It Eyes Top Spot In Rare Diseases
The appointment of Andreas Busch as its new head of R&D represents a boost for Shire which has 17 programs in late-stage development, headed by the potential HAE blockbuster SHP643.
Busch Off to Shire, Moeller Up In Bayer R&D Consolidation; Xofigo Trial Turns Up Safety Issue
Bayer is combining its research and development organization in one unit. Discovery head Andreas Busch is leaving to join Shire while development head Joerg Moeller takes overall control. Meanwhile, Xofigo was linked to more fractures and deaths than the control arm in a prostate cancer trial.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.